Clinical Trials in the USA / NCT06323980
Active, not recruiting
Not applicable
INHANCE Stemless Reverse Shoulder IDE
NCT06323980 · tracked via the Priya Life Science USA tracker
Condition(s) studied
ArthroplastyReplacementShoulder
Investigational drug(s) / intervention(s)
Reverse Total Shoulder
Reverse Total Shoulder: Uncemented Reverse Total Shoulder
Study summary
2:1 Randomized, Controlled, Multi-Center, Prospective, Pre-Market Study of the INHANCE Stemless Reverse Cementless Total Shoulder.
Eligibility
Inclusion Criteria:
1. Individuals requiring reverse total shoulder replacement for a severely painful, disabling, arthritic joint (i.e. osteoarthritis, post-traumatic arthritis and rotator cuff arthropathy).
2. Individuals who are anatomically and structurally suited to receive the implants and have a functional deltoid muscle.
3. Individuals who are able to read and comprehend the informed patient consent document and are willing and able to provide informed patient consent for participation in the study and have authorized the transfer of their information to DePuy Synthes.
4. Individuals who are willing and able to return for follow-up as specified by the study protocol.
5. Individuals who are a minimum age of 22 years at the time of consent.
6. Individuals who are willing and able to complete the Patient Reported Outcome Measure questionnaires (PROMs) as specified by the study protocol.
Exclusion Criteria:
1. BMI \> 40 kg/m2
2. Individuals have active, uncontrolled local infection or systemic infection.
3. Patients who have not reached skeletal maturity, regardless of age.
4. Either preoperatively or intraoperatively and per standard of care medical assessment, bone stock in the proximal humerus or glenoid fossa is determined to be inadequate for supporting the INHANCE humeral stemless components (NOTE: exclusion applies to both arms of the study, i.e., bone stock to be evaluated independent of randomized treatment assignment).
5. Intraoperatively and per treating physician's assessment of bone quality, bone is determined to be too soft or porous to support the implant or that is too hard or brittle to allow for proper bone preparation and fixation, i.e. osteoporosis or sclerotic bone, or tumor(s) of the supporting bone structure, where there could be considerable migration of the prosthesis and/or a chance of fracture of the humerus or glenoid.
6. Fractures of the proximal humerus that could compromise the fixation of the INHANCE reverse humeral stemless components.
7. Patients who have undergone previous treatment on the study shoulder that may compromise fixation of the INHANCE reverse humeral stemless component.
8. Revision of a failed hemi, total or reverse shoulder arthroplasty.
9. Patient is receiving, or is scheduled to receive, treatment that the Investigator considers could affect bone quality, such as chemotherapy or high dose corticosteroids.
10. Individuals who are bedridden per the Investigator's determination.
11. Individuals that have participated in a clinical investigation with an investigational product (drug or device) in the last three months.
12. Individuals currently involved in any personal injury litigation, medical-legal or worker's compensation claims.
13. Individuals, in the opinion of the Investigator, who are drug or alcohol abusers or have psychological disorders that could affect their ability to complete patient reported questionnaires or be compliant with follow-up requirements.
14. Patients with a known medical condition that the Investigator believes would impact the study outcomes (including, but not limited to osteomyelitis, Paget's disease, neuropathies such as Charcot's disease, metastatic or neoplastic disorders).
15. Patient has a medical condition with less than 2 years life expectancy.
16. Patients who are known to be pregnant or breastfeeding.
17. Known polyethylene and/or metal sensitivity or allergy.
18. Contralateral side has been enrolled in the study or has received a total shoulder operation within the last 6 months
19. Otherwise determined by the investigator to be medically unsuitable for participation in this study
20. Patient is a member of a vulnerable population (i.e., incarcerated individuals - those incarcerated for at least one month and considered to be an inmate)
Primary outcome measure(s)
- Constant Murley Score (CMS) — Pre-op, 2 years
Primary effectiveness endpoint - Adjusted Constant-Murley Change from Baseline (ACM CFB) at 2 years post-operative. The CMS is a 100 point scale, the higher the score, the higher the quality of the function. ACM will be obtained by dividing the raw score by the relative score. - Removal of any system component — 2 year
No removal of any system component - Revision of any system component — 2 year
No revision of any system component - Reoperation of any system component — 2 year
No reoperation of any system component - Supplemental Fixation of any system component — 2 year
No supplemental fixation of any system component - Radiolucent Lines (Humeral & Glenoid) — 2 year
No humeral or glenoid radiolucent line greater than 2mm is present in 50% or more zones - Migration and Tilt (Humeral & Glenoid) — 2 year
No conclusive evidence of migration and tilt (greater than 5mm migration and greater than 10 degrees tilt) of the humeral or glenoid component
Trial sites (15)
| Facility | City | Region | Status |
|---|---|---|---|
| Orthopedic Center of Palm Beach County | Atlantis | Florida | |
| Boston Bone & Joint Institute BBJI Formerly BSSC | Waltham | Massachusetts | |
| Trinity Health Grand Rapids | Grand Rapids | Michigan | |
| Missouri Orthopaedic Institute (MOI) | Columbia | Missouri | |
| OrthoCarolina Research Institute Charlotte | Charlotte | North Carolina | |
| Duke Orthopaedics of Raleigh | Raleigh | North Carolina | |
| Crystal Clinic Orthopaedic Center | Akron | Ohio | |
| Lindner Research Center | Cincinnati | Ohio | |
| The Cleveland Clinic Foundation | Cleveland | Ohio | |
| Slocum Center for Orthopaedics and Sports Medicine | Eugene | Oregon | |
| St. Luke's University Health Network | Bethlehem | Pennsylvania | |
| Rothman Orthopaedics Institute | Philadelphia | Pennsylvania | |
| MTBJ a division of Tennessee Orthaepedic Alliance | Columbia | Tennessee | |
| University of Utah | Salt Lake City | Utah | |
| Mary Washington Orthopedics in affiliation with FOA | Fredericksburg | Virginia |
More DePuy Orthopaedics trials in the USA
ATTUNE Revision System in the Revision Total Knee Arthroplasty Population
Active, not recruiting
ATTUNE® Revision- Complex Primary in Total Knee Arthroplasty Population
Active, not recruiting
EMPHASYS Cup Positioning in THA With Non-Invasive Navigation (Velys Hip Navigation (VHN))
Recruiting
14022 ATTUNE Cementless RP Clinical Performance Evaluation
Active, not recruiting
Other trials for the same condition
Triathlon All-Polyethylene Tibia Outcomes Study
Active, not recruiting
ATI Evidence-based Guide Investigating Clinical Services
Active, not recruiting
Triathlon Tritanium Cone Augments Outcomes Study
Active, not recruiting
Official registry record
This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.
View NCT06323980 on ClinicalTrials.gov ↗ ← All trials in the USA